Antibodies used in ELISA are produced through one of three main methods: immunizing animals to collect polyclonal antibodies from their blood, fusing immune cells with cancer cells to create monoclonal antibody-producing hybrids, or engineering them in bacteria using recombinant DNA techniques. Each method has trade-offs in cost, consistency, and specificity, and the choice depends on what the ELISA needs to detect and how precise it needs to be.
Polyclonal Antibodies: Immunizing Animals
The oldest and most straightforward method involves injecting an animal with the target molecule (called an antigen) and letting its immune system do the work. The animal produces a range of antibodies that recognize different parts of the antigen, which is why they’re called “polyclonal.” Rabbits and guinea pigs are the most common choices. Guinea pigs tend to be particularly reliable responders, producing consistent results from one animal to the next.
The process takes weeks. Animals receive a series of injections spaced two to three weeks apart, with each injection boosting the immune response. After the third injection, a small blood sample is tested to see whether the animal is producing strong antibodies. If it is, one final injection is given before a larger blood collection. If the animal still hasn’t responded after a fourth injection, it’s unlikely to produce useful antibodies at all. From start to finish, the immunization schedule for rabbits runs roughly 10 to 12 weeks, while guinea pigs may take slightly longer, around 14 to 16 weeks, before the final collection.
Once collected, the blood is processed to separate the serum, which contains the antibodies. The result is a mixture of many different antibody types, all targeting the same antigen but binding to different spots on its surface. This broad recognition can be an advantage in some ELISA formats, since the antibodies can still grab the target even if one binding site is blocked or slightly altered. The downside is batch-to-batch variation: every new animal produces a slightly different mix.
Monoclonal Antibodies: Hybridoma Technology
When an ELISA needs an antibody that recognizes one precise spot on a target molecule and does so identically every time, monoclonal antibodies are the standard. These come from a technique called hybridoma technology, developed in the 1970s, that merges an immune cell with a cancer cell to create a self-renewing antibody factory.
It starts similarly to polyclonal production: a mouse is immunized with the antigen. Once the mouse mounts a strong immune response, its spleen is removed to harvest the activated B cells (the immune cells that produce antibodies). These B cells are then fused with myeloma cells, a type of cancer cell that can divide indefinitely in culture. The fusion is typically triggered by a chemical called polyethylene glycol, which pushes the outer membranes of the two cell types together until they merge into a single cell with combined DNA. A newer technique called electrofusion uses a brief electric field to achieve the same result more efficiently.
The fused cells are called hybridomas, but the fusion process is messy. The culture dish contains hybridomas, unfused B cells, and unfused myeloma cells all mixed together. To isolate only the hybridomas, the cells are grown for 10 to 14 days in a special selection medium called HAT medium. This medium contains a chemical that blocks one of the two pathways cells use to build DNA. Unfused myeloma cells lack the gene needed to use the backup pathway, so they die. Unfused B cells survive briefly but have a limited natural lifespan and die within days. Only the hybridomas, which inherited the cancer cell’s ability to keep dividing and the B cell’s backup DNA pathway, survive and multiply.
Each surviving hybridoma clone produces a single type of antibody. Researchers screen these clones to find the one that binds the target antigen most effectively, then grow it in large quantities. Because every cell in the clone is genetically identical, the antibody it produces is perfectly consistent from batch to batch, indefinitely.
Recombinant Antibodies: Engineering in Bacteria
A more modern approach skips animal immunization entirely and builds antibodies using genetic engineering. The most common technique is phage display, where the genes encoding antibody fragments are inserted into viruses that infect bacteria. Each virus displays a different antibody fragment on its surface, creating a library of billions of candidates.
To find a useful antibody, the library is exposed to the target antigen. Viruses carrying antibody fragments that bind the target stick to it, while non-binders are washed away. The bound viruses are then collected, amplified by infecting fresh bacteria, and put through the process again with stricter washing conditions. After two or three rounds of this “panning,” the surviving candidates are highly specific binders.
The antibody fragments selected through phage display are typically smaller than full-size antibodies. A common format is the Fab fragment, which contains just the portion of an antibody responsible for binding. These smaller fragments are more stable and easier to produce in large quantities using E. coli bacteria, a workhorse organism in biotechnology. One real-world example: researchers built a fully human antibody library from blood samples of celiac disease patients and used phage display to select antibody fragments capable of detecting gluten in food, which were then incorporated into an ELISA.
Recombinant antibodies offer a major advantage in reproducibility. Because the antibody’s gene sequence is known and stored digitally, anyone can reproduce the exact same antibody without needing a living animal or a frozen hybridoma cell line.
Purification: Isolating the Antibodies
Regardless of how the antibodies are produced, they need to be separated from the soup of other proteins in the culture medium or animal serum. The most common purification method uses Protein A or Protein G, two naturally occurring bacterial proteins that bind tightly to antibodies. These proteins are attached to a resin packed into a column. When the crude antibody mixture is poured through, antibodies stick to the column while everything else flows through.
Protein G binds antibodies from most species more tightly than Protein A, which sounds like a clear advantage, but it creates a trade-off. Because the binding is stronger, harsher acidic conditions are needed to release the antibodies afterward, and some antibodies lose their function during that step. The choice between Protein A and Protein G depends on the antibody species and subtype.
Enzyme Conjugation: Making Antibodies Detectable
An ELISA works by producing a visible color change when the target molecule is present. To make this happen, at least one antibody in the assay must be linked to an enzyme that triggers a color reaction. The two most common enzymes are horseradish peroxidase (HRP) and alkaline phosphatase (AP). When a chemical substrate is added to the plate, these enzymes convert it into a colored product that can be measured with a light-reading instrument.
Some detection antibodies are instead linked to biotin, a small molecule that binds extremely tightly to a protein called streptavidin. The streptavidin is then linked to HRP or AP. This extra step amplifies the signal because multiple enzyme molecules end up clustered at each binding site, making the assay more sensitive to low concentrations of the target.
How Capture and Detection Antibodies Differ
A sandwich ELISA, the most common format for measuring proteins in blood or other fluids, uses two antibodies that must recognize different parts of the target molecule. The capture antibody is attached to the bottom of a plastic well on the ELISA plate, typically by overnight incubation in a carbonate-bicarbonate or phosphate buffer that helps the antibody stick to the polystyrene surface. Its job is to grab the target molecule out of the sample and hold it in place.
The detection antibody is added afterward and binds to a different spot on the now-immobilized target. Because these two antibodies must recognize non-overlapping regions, they’re carefully selected and validated as a matched pair. Using the same antibody for both roles wouldn’t work, since the capture antibody would already be occupying the binding site.
Validation Before the Antibody Ships
Before antibodies are packaged into ELISA kits, they undergo rigorous testing. Specificity is checked by running the assay against known positive samples (containing the target) and known negative samples (without it) to confirm the antibody doesn’t cross-react with similar molecules. Sensitivity is evaluated through serial dilutions, testing progressively smaller amounts of the target to find the lowest concentration the assay can reliably detect.
Performance is also benchmarked against other established diagnostic methods to ensure results are consistent. Validation studies analyze a statistically significant number of samples and calculate metrics including sensitivity, specificity, positive predictive value, and negative predictive value. Only after meeting these benchmarks is the antibody considered ready for diagnostic or research use.